Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.

Détails

Ressource 1Télécharger: 18637757_Postprint.pdf (683.22 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_589A6B4C7D09
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.
Périodique
Clinical Infectious Diseases
Auteur(s)
Segal B.H., Herbrecht R., Stevens D.A., Ostrosky-Zeichner L., Sobel J., Viscoli C., Walsh T.J., Maertens J., Patterson T.F., Perfect J.R., Dupont B., Wingard J.R., Calandra T., Kauffman C.A., Graybill J.R., Baden L.R., Pappas P.G., Bennett J.E., Kontoyiannis D.P., Cordonnier C., Viviani M.A., Bille J., Almyroudis N.G., Wheat L.J., Graninger W., Bow E.J., Holland S.M., Kullberg B.J., Dismukes W.E., De Pauw B.E.
ISSN
1537-6591
Statut éditorial
Publié
Date de publication
2008
Peer-reviewed
Oui
Volume
47
Numéro
5
Pages
674-683
Langue
anglais
Résumé
Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes. Major fungal diseases that are discussed include invasive disease due to Candida species, Aspergillus species and other molds, Cryptococcus neoformans, Histoplasma capsulatum, and Coccidioides immitis. We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge.
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/03/2009 18:12
Dernière modification de la notice
20/08/2019 15:12
Données d'usage